Exxua XR Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Exxua Availability in 2026

Exxua (Gepirone) represents the first new class of oral antidepressant in decades — a selective 5-HT1A receptor partial agonist approved for major depressive disorder in adults. For clinicians who have long needed an antidepressant without the burden of sexual dysfunction or significant weight gain, Exxua is a welcome addition to the pharmacologic toolbox.

However, prescribing Exxua in early 2026 comes with practical challenges. This briefing covers what you need to know about availability, distribution, insurance considerations, and tools to support your patients.

Timeline: From Approval to Availability

Understanding the timeline helps contextualize the current situation:

• September 2023: FDA approves Exxua (Gepirone) extended-release tablets for MDD in adults — NDA 021164, Fabre-Kramer Pharmaceuticals.
• June 2025: Aytu BioPharma signs exclusive agreement with Fabre-Kramer to commercialize Exxua in the United States.
• Q4 2025: Aytu begins commercial preparations, pharmacy onboarding, and payer engagement.
• January 20, 2026: Nationwide commercial launch. Exxua becomes available through retail and Aytu RxConnect pharmacies.

The 27-month gap between FDA approval and commercial availability is unusual but reflects the need for a commercialization partner. Fabre-Kramer developed the drug but lacked the commercial infrastructure to launch it independently.

Prescribing Implications

Clinical Profile

Exxua is a selective partial agonist of the 5-HT1A receptor with a distinct profile from SSRIs and SNRIs:

• Efficacy: Two positive pivotal trials showed statistically significant reduction in HAMD-17 scores vs. placebo (~2.5 points on a 52-point scale). Effect sizes are comparable to other approved antidepressants.
• Sexual dysfunction: No labeling for sexual side effects — a clinically meaningful differentiator for patients who discontinue SSRIs/SNRIs due to sexual dysfunction.
• Weight: No clinically significant weight gain vs. placebo in clinical trials.
• QT prolongation: Exxua can prolong the QTc interval. Obtain baseline ECG and electrolytes. Contraindicated in patients with QTc > 450 msec or congenital long QT syndrome.
• CYP3A4 metabolism: Contraindicated with strong CYP3A4 inhibitors. Reduce dose by 50% with moderate CYP3A4 inhibitors.

For a comprehensive clinical review, see our detailed article on Exxua's mechanism of action.

Dosing

• Start: 18.2 mg once daily with food
• Day 4: May increase to 36.3 mg once daily
• After Day 7: May increase to 54.5 mg once daily
• After an additional week: May increase to 72.6 mg once daily
• Geriatric / Renal impairment (CrCl < 50): Start 18.2 mg, max 36.3 mg after 7 days
• Moderate hepatic impairment (Child-Pugh B): Max 36.3 mg after 7 days
• Severe hepatic impairment (Child-Pugh C): Contraindicated

Current Availability Picture

Exxua is not in a formal FDA drug shortage. However, real-world availability is limited by its distribution model:

• Primary channel: Aytu RxConnect pharmacy network (~1,000+ participating pharmacies)
• Major retail chains: CVS, Walgreens, and Rite Aid may not stock Exxua or may need to special-order it
• Independent pharmacies: Many independents can order Exxua through specialty distributors and may be more responsive than chain pharmacies

Practically, this means your patients may call multiple pharmacies before finding one that carries Exxua. Setting expectations at the point of prescribing can reduce frustration.

Cost and Access Considerations

Cash Price

Exxua's retail cash price is approximately $1,500-$1,800/month for 30 tablets, depending on strength. No generic is available (NCE exclusivity through September 2028).

Insurance Coverage

Most commercial and Medicare Part D plans are still evaluating Exxua for formulary inclusion. Current trends:

• Prior authorization: Required by most plans
• Step therapy: Many plans require trial-and-failure documentation with generic SSRIs/SNRIs
• Formulary tier: Expected to be placed on specialty or non-preferred brand tiers, similar to Auvelity

Aytu RxConnect Program

Aytu offers the RxConnect program, which provides:

• Reduced out-of-pocket costs at participating pharmacies
• Prior Authorization Support Program to assist your office with PA documentation
• Approximately 85% of Aytu's ADHD prescriptions (for their other products) already flow through RxConnect, indicating a mature network

Tools and Resources for Providers

• Medfinder for Providers: Help your patients locate pharmacies with Exxua in stock. Medfinder's search tool can save your staff time fielding availability calls.
• Aytu Prior Authorization Support: Download login instructions at exxuahcp.com/savings for PA support resources.
• Patient education: Direct patients to our patient-facing shortage update and pharmacy search tips to empower them in the process.

Looking Ahead

Several factors suggest Exxua availability will improve throughout 2026:

• Aytu BioPharma is actively expanding the RxConnect pharmacy network
• Insurance formulary reviews are ongoing, and more plans are expected to add Exxua coverage
• Prescriber and patient awareness is growing, which will drive pharmacy stocking decisions
• Projected U.S. revenue for Exxua is $46 million in 2026 (up from $17 million in 2025), indicating expected growth in prescriptions and distribution

For providers managing patients who need immediate treatment and can't access Exxua, our guide on alternatives to Exxua covers the most relevant options, including Buspirone augmentation, Bupropion, Auvelity, and Vortioxetine.

Final Thoughts

Exxua fills a genuine clinical need — an oral antidepressant for MDD that avoids the sexual dysfunction and weight gain that drive non-adherence to SSRIs and SNRIs. The current availability challenges are a function of its recent launch and specialty distribution model, not a supply shortage.

Providers can best support their patients by setting realistic expectations about pharmacy availability, leveraging the Aytu RxConnect network and PA support tools, and using Medfinder for Providers to locate stock. As distribution matures throughout 2026, prescribing Exxua should become increasingly straightforward.

For a step-by-step workflow guide, see our companion post: How to help your patients find Exxua in stock.